CytomX Therapeutics to Present at Upcoming December Investor Conferences

Company Overview - CytomX Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on oncology, developing novel conditionally activated, masked biologics aimed at localizing treatment to the tumor microenvironment [3] - The company utilizes its PROBODY therapeutic platform to create safer and more effective cancer therapies, with a pipeline that includes antibody-drug conjugates (ADCs), T-cell engagers, and immune modulators [3] Clinical Pipeline - Current clinical-stage candidates include CX-2051, a masked ADC targeting epithelial cell adhesion molecule (EpCAM) with a topoisomerase-1 inhibitor payload, and CX-801, a masked interferon alpha-2b PROBODY cytokine [3] - CX-2051 has potential applications in various EpCAM-expressing epithelial cancers, including colorectal cancer (CRC), and was developed in collaboration with ImmunoGen [3] - CX-801 is designed for broad applicability in both immuno-oncology sensitive and insensitive tumors [3] Strategic Collaborations - CytomX has established partnerships with leading companies in oncology, including Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna [3] Upcoming Events - Management will participate in the 8th Annual Evercore Healthcare Conference on December 2, 2025, and the Piper Sandler 37th Annual Healthcare Conference on December 4, 2025 [2] - A live webcast of the presentations will be available on CytomX's website, and management will hold one-on-one meetings with registered investors [2]